CN1590373A - 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 - Google Patents

1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 Download PDF

Info

Publication number
CN1590373A
CN1590373A CNA2004100586743A CN200410058674A CN1590373A CN 1590373 A CN1590373 A CN 1590373A CN A2004100586743 A CNA2004100586743 A CN A2004100586743A CN 200410058674 A CN200410058674 A CN 200410058674A CN 1590373 A CN1590373 A CN 1590373A
Authority
CN
China
Prior art keywords
hydroxyphenyl
hydroxy
tartrate
propyl alcohol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100586743A
Other languages
English (en)
Chinese (zh)
Inventor
J·P·雷恩维勒
T·G·小希内
S·W·沃林斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1590373A publication Critical patent/CN1590373A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
CNA2004100586743A 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 Pending CN1590373A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28
US60/200,673 2000-04-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB011171715A Division CN1210262C (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法

Publications (1)

Publication Number Publication Date
CN1590373A true CN1590373A (zh) 2005-03-09

Family

ID=22742684

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004100586743A Pending CN1590373A (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法
CNB011171715A Expired - Fee Related CN1210262C (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB011171715A Expired - Fee Related CN1210262C (zh) 2000-04-28 2001-04-27 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法

Country Status (27)

Country Link
US (1) US6645986B2 (US06573293-20030603-C00009.png)
EP (2) EP1477479A1 (US06573293-20030603-C00009.png)
JP (2) JP3615496B2 (US06573293-20030603-C00009.png)
KR (1) KR100442718B1 (US06573293-20030603-C00009.png)
CN (2) CN1590373A (US06573293-20030603-C00009.png)
AR (1) AR028376A1 (US06573293-20030603-C00009.png)
AT (1) ATE277014T1 (US06573293-20030603-C00009.png)
AU (1) AU781436B2 (US06573293-20030603-C00009.png)
BR (1) BR0101630A (US06573293-20030603-C00009.png)
CA (1) CA2345582C (US06573293-20030603-C00009.png)
CZ (1) CZ20011471A3 (US06573293-20030603-C00009.png)
DE (1) DE60105689T2 (US06573293-20030603-C00009.png)
DK (1) DK1151995T3 (US06573293-20030603-C00009.png)
ES (1) ES2227071T3 (US06573293-20030603-C00009.png)
HK (1) HK1040246B (US06573293-20030603-C00009.png)
HU (1) HUP0101723A3 (US06573293-20030603-C00009.png)
ID (1) ID30006A (US06573293-20030603-C00009.png)
IL (1) IL142705A0 (US06573293-20030603-C00009.png)
IN (1) IN191027B (US06573293-20030603-C00009.png)
PL (1) PL347298A1 (US06573293-20030603-C00009.png)
PT (1) PT1151995E (US06573293-20030603-C00009.png)
RU (1) RU2203888C2 (US06573293-20030603-C00009.png)
SI (1) SI1151995T1 (US06573293-20030603-C00009.png)
TR (1) TR200402696T4 (US06573293-20030603-C00009.png)
TW (1) TW200505858A (US06573293-20030603-C00009.png)
YU (1) YU27701A (US06573293-20030603-C00009.png)
ZA (1) ZA200103320B (US06573293-20030603-C00009.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098765A1 (en) * 2000-06-21 2001-12-27 Bioarray Solutions, Ltd. Multianalyte molecular analysis
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN1930304B (zh) * 2003-11-21 2016-01-06 Anp技术公司 不对称支化的聚合物缀合物和微阵列检测
DE602006019709D1 (US06573293-20030603-C00009.png) 2005-05-02 2011-03-03 Anp Technologies Inc

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat

Also Published As

Publication number Publication date
AU3889601A (en) 2001-11-01
JP2001354651A (ja) 2001-12-25
PT1151995E (pt) 2004-11-30
DE60105689D1 (de) 2004-10-28
EP1151995B1 (en) 2004-09-22
BR0101630A (pt) 2001-12-04
AU781436B2 (en) 2005-05-26
ES2227071T3 (es) 2005-04-01
CN1321638A (zh) 2001-11-14
ATE277014T1 (de) 2004-10-15
HUP0101723A3 (en) 2003-03-28
ID30006A (id) 2001-11-01
PL347298A1 (en) 2001-11-05
YU27701A (sh) 2003-04-30
IN191027B (US06573293-20030603-C00009.png) 2003-09-13
CZ20011471A3 (cs) 2002-02-13
DK1151995T3 (da) 2004-12-13
AR028376A1 (es) 2003-05-07
CA2345582A1 (en) 2001-10-28
TW200505858A (en) 2005-02-16
HK1040246B (zh) 2005-10-28
JP2004196823A (ja) 2004-07-15
CN1210262C (zh) 2005-07-13
RU2203888C2 (ru) 2003-05-10
EP1151995A1 (en) 2001-11-07
KR20010098960A (ko) 2001-11-08
IL142705A0 (en) 2002-03-10
HU0101723D0 (en) 2001-07-30
HK1040246A1 (en) 2002-05-31
US6645986B2 (en) 2003-11-11
EP1477479A1 (en) 2004-11-17
SI1151995T1 (en) 2004-12-31
ZA200103320B (en) 2002-10-24
KR100442718B1 (ko) 2004-08-02
US20020016465A1 (en) 2002-02-07
TR200402696T4 (tr) 2004-11-22
CA2345582C (en) 2006-05-30
DE60105689T2 (de) 2005-11-10
JP3615496B2 (ja) 2005-02-02
HUP0101723A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
CA2228752C (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
CN1210262C (zh) 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法
BRPI0921561B1 (pt) Derivado de 3-fenil-3-metóxi-pirrolidina, composição farmacêutica, uso do derivado de 3- fenil-3-metóxi-pirrolidina
CN1048247C (zh) 神经保护的苯并二氢吡喃化合物
RU2192415C1 (ru) Способ получения мезилат тригидрата 1-(4-гидроксифенил)-2-(4-гидрокси-4-фенилпиперидин-1-ил)-1-пропанола и промежуточные продукты
CZ223896A3 (en) Condensation and addition polymers with n,n - bridge bis-tetramethylpiperidinyloxy groupings
MXPA01004288A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)- 2-(4-hydroxy-4- phenylpiperidin-1-yl)- 1-propanol
MXPA98001149A (en) Metansulfonate of (1s, 2s) -1- (4-hydroxypenyl) -2- (4-hydroxy-4-phenylpiperidin-1-il) -1-propanoltrihydrate and use of mi
MXPA01004289A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl) -2-(4-hydroxy-4- phenylpiperidin -1-yl) -1-propanol and intermediates useful therefor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070644

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070644

Country of ref document: HK